%0 Journal Article
%T Molecular Aggregation of Marketed Recombinant FVIII Products: Biochemical Evidence and Functional Effects
%A Carla Valsecchi
%A Enrico Di Stasio
%A Federico Berruti
%A Flora Peyvandi
%A Isabella Garagiola
%A Maria Basso
%A Monica Sacco
%A Raimondo De Cristofaro
%A Stefano Lancellotti
%J Archive of "TH Open: Companion Journal to Thrombosis and Haemostasis".
%D 2019
%R 10.1055/s-0039-1688413
%X Background £¿Recombinant (rec-) coagulation factor VIII concentrates available for hemophilia A (HA) treatment differ in cell line production and structure, which could affect their pharmacodynamics and immunogenicity. Clinical trials showed that previously untreated patients with severe HA present higher rates of inhibitor development if treated with rec-FVIII products and that differences do exist as to inhibitor's formation among different rec-FVIII products. This finding could arise from several causes, such as absence of von Willebrand factor, different glycosylation profiles, or processes of molecular aggregation of the recombinant FVIII molecules
%K recombinant FVIII
%K molecular aggregation
%K Hemophilia A
%K dynamic light scattering
%K FVIII inhibitors
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6524925/